Regulus Therapeutics Inc  

(Public, NASDAQ:RGLS)   Watch this stock  
Find more results for RGLS
6.54
+0.31 (4.98%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.25 - 6.63
52 week 5.40 - 11.88
Open 6.27
Vol / Avg. 40,668.00/79,486.00
Mkt cap 283.48M
P/E     -
Div/yield     -
EPS -0.60
Shares 43.35M
Beta     -
Inst. own 33%
Aug 11, 2014
Q2 2014 Regulus Therapeutics Inc Earnings Release (Estimated) Add to calendar
May 22, 2014
Regulus Therapeutics Inc Annual Shareholder Meeting
May 15, 2014
Regulus Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Q1 2014 Regulus Therapeutics Inc Earnings Conference Call
May 8, 2014
Q1 2014 Regulus Therapeutics Inc Earnings Release
May 7, 2014
Regulus Therapeutics Inc at Deutsche Bank Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -781.18% -95.40%
Operating margin -786.57% -96.82%
EBITD margin - -83.82%
Return on average assets -41.35% -16.48%
Return on average equity -55.03% -24.00%
Employees 76 -
CDP Score - -

Address

Suite 210, 3545 John Hopkins Court
SAN DIEGO, CA 92121
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regulus Therapeutics Inc., is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012, the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. Effective March 5, 2014, Sanofi SA of France acquired an undisclosed minority stake in Regulus Therapeutics Inc.

Officers and directors

Stelios B. Papadopoulos Ph.D. Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Kleanthis G. Xanthopoulos Ph.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Neil W. Gibson Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
David Szekeres Chief Business Officer, General Counsel, Corporate Secretary
Age: 40
Bio & Compensation  - Reuters
Paul C. Grint M.D. Chief Medical Officer
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Director
Age: 59
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Bruce L. A. Carter Ph.D. Independent Director
Bio & Compensation  - Reuters
Mark G. Foletta CPA Independent Director
Age: 53
Bio & Compensation  - Reuters